Insider Selling: Alphatec (NASDAQ:ATEC) EVP Sells $438,793.74 in Stock

Alphatec Holdings, Inc. (NASDAQ:ATEC) EVP David Sponsel sold 21,106 shares of the business’s stock in a transaction dated Wednesday, December 10th. The stock was sold at an average price of $20.79, for a total value of $438,793.74. Following the transaction, the executive vice president directly owned 439,767 shares of the company’s stock, valued at $9,142,755.93. This represents a 4.58% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

David Sponsel also recently made the following trade(s):

• On Monday, December 8th, David Sponsel sold 988 shares of Alphatec stock. The shares were sold at an average price of $21.45, for a total value of $21,192.60.
• On Friday, October 24th, David Sponsel sold 70,000 shares of Alphatec stock. The stock was sold at an average price of $16.18, for a total value of $1,132,600.00.
• On Friday, September 19th, David Sponsel sold 2,555 shares of Alphatec stock. The shares were sold at an average price of $15.34, for a total value of $39,193.70.
• On Thursday, September 18th, David Sponsel sold 137,445 shares of Alphatec stock. The stock was sold at an average price of $15.09, for a total transaction of $2,074,045.05.

Alphatec Price Performance

NASDAQ:ATEC opened at $19.96 on Monday. The company has a debt-to-equity ratio of 43.02, a current ratio of 1.99 and a quick ratio of 1.24. Alphatec Holdings, Inc. has a one year low of $8.69 and a one year high of $22.66. The company has a fifty day moving average price of $18.42 and a 200 day moving average price of $15.12. The stock has a market cap of $2.97 billion, a P/E ratio of -19.19 and a beta of 1.08.

Alphatec (NASDAQ:ATEC) last posted its quarterly earnings data on Thursday, October 30th. The medical technology company reported $0.03 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.06) by $0.09. The company had revenue of $196.50 million for the quarter, compared to the consensus estimate of $182.78 million. The business’s revenue for the quarter was up 30.4% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.28) EPS. Analysts anticipate that Alphatec Holdings, Inc. will post -1.08 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of ATEC. Vanguard Group Inc. boosted its stake in shares of Alphatec by 2.4% in the 3rd quarter. Vanguard Group Inc. now owns 6,815,058 shares of the medical technology company’s stock valued at $99,091,000 after purchasing an additional 158,295 shares in the last quarter. American Century Companies Inc. boosted its position in Alphatec by 2.6% in the third quarter. American Century Companies Inc. now owns 6,336,491 shares of the medical technology company’s stock valued at $92,133,000 after buying an additional 159,330 shares in the last quarter. Royal Bank of Canada boosted its position in Alphatec by 10.8% in the first quarter. Royal Bank of Canada now owns 3,527,939 shares of the medical technology company’s stock valued at $35,773,000 after buying an additional 342,656 shares in the last quarter. Geode Capital Management LLC grew its stake in Alphatec by 7.4% during the second quarter. Geode Capital Management LLC now owns 2,697,541 shares of the medical technology company’s stock worth $29,946,000 after buying an additional 185,297 shares during the last quarter. Finally, Next Century Growth Investors LLC increased its holdings in shares of Alphatec by 22.8% during the second quarter. Next Century Growth Investors LLC now owns 2,060,735 shares of the medical technology company’s stock worth $22,874,000 after buying an additional 382,057 shares in the last quarter. 66.35% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

ATEC has been the subject of a number of research reports. Morgan Stanley set a $23.00 price objective on Alphatec in a research report on Tuesday, December 2nd. HC Wainwright upped their target price on Alphatec from $20.00 to $24.00 and gave the company a “buy” rating in a research note on Friday, October 31st. Wells Fargo & Company raised their target price on Alphatec from $14.00 to $16.00 and gave the stock an “overweight” rating in a research report on Thursday, October 16th. Piper Sandler reissued an “overweight” rating and issued a $25.00 price target (up previously from $20.00) on shares of Alphatec in a report on Friday, October 31st. Finally, Canaccord Genuity Group increased their price objective on shares of Alphatec from $20.00 to $25.00 and gave the company a “buy” rating in a research note on Friday, October 31st. Nine research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $22.45.

Alphatec Company Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.